Aardvark Therapeutics, a clinical‑stage biopharma company focused on hunger suppression, is now the target of a class action lawsuit filed in the Southern District of California. The case alleges that the company misled investors about the safety and prospects of its lead compound, ARD‑101, a gut‑restricted small‑molecule designed to trigger natural peptide signaling pathways.
When Gut‑Signaling Hits a Heart Barrier
ARD‑101 was pitched as a safer alternative to injectable peptide drugs, working by activating Bitter Taste Receptors (TAS2Rs) in the gut to release GLP‑1 and cholecystokinin (CCK) — hormones central to metabolic and weight‑loss research.
But in February 2026, Aardvark voluntarily paused its Phase 3 HERO trial after “reversible cardiac observations” appeared in healthy volunteers. By May, the FDA escalated the pause into a full clinical hold, halting all ongoing studies. The company’s stock collapsed from its $16 IPO price to under $5, sparking investor claims that safety risks had been concealed.
The Risks of Chasing the GLP‑1 Gold Rush
The lawsuit underscores the intense competition in the metabolic therapy market. With Novo Nordisk’s GLP‑1 drugs dominating headlines, Aardvark sought to differentiate itself by offering a gut‑restricted small molecule that could mimic peptide release without injections. Investors bought into the promise, but the cardiac safety setback shows how quickly fortunes can reverse in the race to capture the obesity treatment market.
A Setback for Prader‑Willi Syndrome Research
Beyond Wall Street, the pause is a blow to families affected by Prader‑Willi Syndrome (PWS), a rare disorder marked by insatiable hunger. ARD‑101’s HERO trial was one of the most closely watched studies targeting hyperphagia. With the FDA hold in place, a promising new mechanism for managing hunger is sidelined, leaving researchers to look again at peptide‑based approaches.
The case highlights a broader cautionary tale: even therapies designed to harness natural peptide signaling can run into unforeseen safety barriers. For readers tracking the peptide and metabolic space, Aardvark’s troubles are a reminder that the path from lab to clinic is fraught with both scientific and regulatory risk.
Related Coverage: For more on how peptide transparency is reshaping the industry, see our coverage of PrymaLab Research Hub.
2 Responses